Research Advances in Itch Mechanisms of Pediatric Atopic Dermatitis

Authors & Affiliation

Qingyang Zhao, MD | Lin Ma, MD, PhD

Department of Dermatology, Beijing Children's Hospital, Capital Medical University

National Center for Children's Health, Beijing 100045, China

Learning Objectives

Elucidate the core triad: barrier dysfunction, immune dysregulation, neural sensitization

Review novel targets (IL-4Rα, IL-31RA, JAK) and their clinical applications

Discuss future directions for personalized itch management

Key Message

Pediatric AD pruritus is a neuroimmune disorder requiring integrated barrier-immune-neural axis modulation

Conflict of Interest

The authors declare no conflict of interest

Contact

joyqingyang@126.com | bch_maleen@aliyun.com

The Challenge of Pediatric AD: A Vicious Cycle of Pruritus

FLG Mutation and Barrier Defect

FLG mutations lead to a compromised skin barrier, allowing allergens to penetrate the skin. This initiates the cycle of inflammation and pruritus in pediatric atopic dermatitis.

Immune Activation

Allergen penetration triggers immune activation, releasing cytokines like TSLP and IL-33. These cytokines drive intense pruritus, setting off the itch-scratch cycle.

Pruritus and Scratching

Intense pruritus compels children to scratch, causing further barrier damage and inflammation. This perpetuates the cycle, leading to chronic symptoms and complications.

Axon Reflex

Scratching and pruritogens trigger the release of neuromediators (e.g., SP, CGRP) from sensory nerves, which aggravate inflammation, recruit immune cells, and further impair the skin barrier, fueling the cycle.

Impact and Burden

The vicious cycle results in significant consequences, including sleep loss, skin infections, neurocognitive impairment, growth delay, and an annual socio-economic burden of US $1,000–6,000 per child.

Potential Differences in Pruritus Mechanisms: Pediatric vs. Adult AD

Immune Polarity

Pediatric AD is typically marked by a Th2-skewed immune response while adult AD demonstrates a more complex immune polarization, involving Th1, Th17, and Th22 pathways, indicative of chronic inflammation. Elevated levels of IL-33 and IL-9 in pediatric AD may explain the higher prevalence of food allergies in early life, a feature less common in adult cases.

Clinical & Behavioral Correlates

Pediatric pruritus is often inferred from behaviors like rubbing and restlessness, with triggers including novel food and environmental allergens. In adults, pruritus is self-reported and strongly linked to psychological comorbidities such as anxiety and depression, with stress being a major exacerbating factor.

Neural Plasticity

Children with AD have a higher susceptibility to neural sensitization, with the developing nervous system potentially being 'rewired' by NGF and BDNF, leading to hyperinnervation. In adults, chronic signaling results in established peripheral and central sensitization.

Barrier Status

In pediatric AD, primary barrier defects such as FLG mutations are key initiating factors. In adults, barrier dysfunction is more often a consequence of chronic inflammation, scratching, and age-related degradation, rather than a primary cause.

The Core Triad Driving AD Pruritus

1.Epidermal Barrier Disruption

FLG gene mutations lead to a weakened skin barrier, increasing transepidermal water loss (TEWL) and altering pH. This disruption allows allergens to penetrate, triggering keratinocytes to release alarmins like TSLP and IL-33, initiating the inflammatory cascade.

2.Immune Dysregulation (Th2 Skew)

Key Th2 cytokines such as IL-4, IL-13, and IL-31 are overexpressed in AD. These cytokines directly activate and sensitize sensory neurons, downregulate barrier proteins, and perpetuate chronic inflammation, driving the itch-scratch cycle.

3.Neural Rewiring & Sensitization

NGF and BDNF induce hyperinnervation in the epidermis. IL-31 signaling in sensory neurons via JAK-STAT pathways enhances neuronal responsiveness (e.g., to TRPV1 agonists), leading to peripheral hyperknesis and central alloknesis, establishing chronic itch.

Central Sensitization & Spinal Cord Processing:

Chronic itch signaling leads to spinal cord sensitization.
Excitatory interneurons (e.g., GRPR+) amplify itch.
Loss of inhibitory control (e.g., GABA, Glycine, NPY) disinhibits itch pathways.
Astrocytes and microglia (via STAT3, LCN2) sustain chronic itch.

Neuroimmune Crosstalk: Key Players

Cytokines: IL-31, IL-4, IL-13, TSLP, IL-33

Receptors & Channels:

GPCRs: Mrgprs (e.g., MrgprX2), PAR2

TRP Channels: TRPV1, TRPA1 (key for non-histaminergic itch)

Cytokine Receptors: IL-31RA, IL-4Rα

Key Intracellular Pathway:

JAK-STAT Signaling – A final common pathway for multiple pruritogenic cytokines.

Transcriptional modulation in DRG neurons

Key Neuromediators: SP, CGRP, BNP, GRP

Key Message: Chronic itch in AD is primarily non-histaminergic, driven by direct neuro-immune communication via these pathways. This explains the limited efficacy of traditional antihistamines.

Immune Cells Amplifying the Itch Signal

Basophils

Rapidly recruited to inflamed skin.
Promote acute and chronic itch via leukotriene and IL-4 release.



Eosinophils

Secrete IL-31 and BDNF.
Promote nerve fiber branching via JAK/STAT and neuroimmune crosstalk.

Mast Cells

IgE/FcεRI pathway:
Histaminergic itch.
MrgprB2/X2 pathway:
Non-histaminergic, chronic itch.

Translating Mechanisms into Treatments

Dupilumab (anti-IL-4Rα) – Blocks IL-4/IL-13.
Nemolizumab (anti-IL-31Rα) – Rapid anti-pruritic effect by blocking direct neuronal activation.
Tezepelumab (anti-TSLP) – Early promise.

JAK Inhibitors: Topical Delgocitinib, Oral Abrocitinib.Target intracellular signaling of multiple pruritogenic cytokines.
PDE4 Inhibitor: Topical Roflumilast.
Tapinarof – Restores barrier function, reduces inflammation (FDA-approved for kids ≥2 yrs, 2024).



Emerging & Potential Targets:

- Neuromodulator Targets: NK1R (Substance P), GRPR, PAR2.
- Ion Channels: TRPV1/TRPA1 antagonists.
- Intracellular Signaling: JAK inhibitors (as shown), BRAF, TEC kinases.

Summary and The Road Ahead

Pediatric AD pruritus is a multidimensional disorder of the barrier-immune-neural axis.

Current Success:

Biologics against Th2 cytokines and JAK inhibitors provide rapid, targeted itch relief.

Future Directions:

1.Combination Therapies: Target multiple pathways (cytokines + neuromodulators + barrier repair).
2.Personalized Medicine: Identify key itch mediators (IL-4 vs IL-13 vs IL-31, PAR2, Mrgprs) for different AD phenotypes and severities.Tailoring treatment based on individual patient's dominant pathway (e.g., IL-31 high vs. TSLP high).
3.Early Intervention: To prevent the "Atopic March" and chronic itch sensitization. Understand the role of pruritic mediators in the Atopic March.
4.Address Central Sensitization: Develop treatments for chronic and neuropathic itch components.